Table 1.
Pediatric subject characteristics and analyses
| Patient Characteristics |
Medications |
Device | ||||||
|---|---|---|---|---|---|---|---|---|
| ID | Sex | Age at Blood Collection, yr | EF/FS | Digoxin | ACE Inhibitor/AT1R Blocker | β-Blocker | Inotropes | VAD |
| Nonfailing (NF) | ||||||||
| 1 | M | 9.7 | NA | N | N | N | N | N |
| 2a | F | 11.8 | NA | N | N | N | N | N |
| 3 | M | 4.3 | NA | N | N | N | N | N |
| Dilated cardiomyopathy (DCM) | ||||||||
| 1 | M | 9.0 | EF 20% | N | N | N | N | YB |
| 2 | M | 11.6 | NA | N | Y | N | Y | N |
| 3 | M | 5.1 | FS 4% | N | N | Y | N | YB |
| 4 | M | 5.2 | EF 21% | N | Y | Y | Y | N |
| 5 | M | 9.8 | EF 7% | N | Y | N | Y | N |
| 6 | M | 2.9 | NA | N | Y | N | Y | N |
| 7a | M | 17.2 | NA | N | Y | N | N | YH |
| 8a | F | 0.6 | NA | N | N | N | N | YB |
| 9 | F | 5.3 | EF 20% | N | N | Y | N | YB |
| 10 | F | 0.4 | EF 20% | N | Y | Y | Y | N |
| 11 | F | 0.7 | EF 24% | Y | Y | N | Y | N |
Inotropes include the following: phosphodiesterase 3 (PDE3), dopamine (Dop), dobutamine (Dob), and epinephrine (Epi). Ventricular assist device (VAD) includes Berlin (B) and Heartware (H). M, male; F, female; Y, yes; N, no; EF, ejection fraction; FS, fractional shortening; NA, not available.